Chadi Nabhan, MD, MBA, FACP

Chadhi Nabhan, MD, MBA, FACP, is a hematologist/oncologist and award-winning host of the “Outspoken Oncology” and “Healthcare Unfiltered” podcasts.

Articles by Chadi Nabhan, MD, MBA, FACP

Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | August 22, 2024
Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD continue their discussion on MRD in CLL during HOP Live 2024.
Afaf Osman, MDThe HemOnc Pulse | August 9, 2024
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 26, 2024
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | July 24, 2024
Among the major dilemmas persisting in CAR-T therapy use is how to balance malignancy risks.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | July 19, 2024
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | September 3, 2024
This episode explores questions in CLL with Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD during HOP Live 2024.
Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 1, 2024
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 28, 2024
Amer Zeidan, MBBS, discusses the unanswered questions in research related to myelodysplastic syndromes.
Sangeetha Venugopal, MDChronic Myeloid Leukemia | June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Chadi Nabhan, MD, MBA, FACPVideo Insights | June 7, 2024
Himachandana Atluri, MD, describes the experience and ins and outs of becoming a new fellow.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 31, 2024
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 24, 2024
Michael Bishop MD; Aaron Goodman, MD; and Rafael Fonseca, MD, discuss bispecifics in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 23, 2024
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 17, 2024
The panel discussed treatment options for Hodgkin lymphoma, maintenance therapy following autologous transplant, and more.